Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atia Shah

Infectious Disease West Covina, CA Medical Doctor

NPI 1710155676 CMS profile 31844

1135 S Sunset Ave, Suite 208, West Covina, CA 91790

Open in the dashboard

General payments

$2,077

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Atia Shah of West Covina, CA is reported in the CMS Open Payments database as having received $2,077 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $417 22
2024 General $179 14
2023 General $196 10
2022 General $135 7
2021 General $144 8
2020 General $159 8
2019 General $847 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atia Shah
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Atia Shah were reported at $417. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Atia Shah Infectious Disease median Middle half National median
2019 $847 $190 $60–$862 $163
2020 $159 $124 $32–$606 $114
2021 $144 $148 $38–$905 $132
2022 $135 $166 $50–$834 $149
2023 $196 $171 $57–$787 $160
2024 $179 $176 $52–$752 $164
2025 $417 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $586 40 payments
  2. ViiV Healthcare Company $488 20 payments
  3. Allergan Inc. $244 11 payments
  4. Gilead Sciences, Inc. $202 9 payments
  5. Melinta Therapeutics, Inc. $168 4 payments
  6. Baxter Healthcare $79 3 payments
  7. Insmed, Inc. $77 4 payments
  8. Merck Sharp & Dohme Corporation $67 4 payments
  9. Shionogi Inc $34 1 payment
  10. Coloplast Corp $28 1 payment
  11. Other $104 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,077 102 payments
Products named General payments · program years 2019–2025
  1. AVYCAZ $751 46 payments
  2. DALVANCE $385 28 payments
  3. TEFLARO $379 28 payments
  4. DOVATO $345 14 payments
  5. EMBLAVEO $135 10 payments
  6. Baxdela $134 2 payments
  7. Arikayce $77 4 payments
  8. CABENUVA $68 3 payments
  9. Hillrom - Monarch Airway Clearance System $49 2 payments
  10. TRIUMEQ $43 2 payments
  11. Other $433 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$395,910

Medicare's payments for the services billed

Medicare patients

791

Average age 76

Services billed

5,168

408 women, 383 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 70%
Chronic kidney disease 62%
Arthritis 58%
Heart failure 57%
Ischemic heart disease 53%
Atrial fibrillation 44%
Alzheimer's or dementia 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AVYCAZ
  • AbbVie, Inc. $45
$45 — —
DALVANCE
  • AbbVie, Inc. $45
$45 — —
TEFLARO
  • AbbVie, Inc. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record